We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Collaboration to Promote Study of the Role of Structural Biology in Disease

By LabMedica International staff writers
Posted on 25 Jan 2012
A major manufacturer of electron microscopes has joined a cooperative research initiative to combine this method with NMR (nuclear magnetic resonance) spectroscopy and X-ray diffraction to accelerate medical discoveries in the fields of infectious diseases and cancer.

The electron microscope manufacturer FEI (Hillsboro, OR, USA) has entered into a Cooperative Research and Development Agreement (CRADA) with the [US] National Institutes of Health (Bethesda, MD, USA), to create a “Living Lab Structural Biology Center” to promote structural biology research through the integration of cryoelectron microscopy (EM), NMR spectroscopy, and X-ray diffraction (XRD).

The research program, which will be centered on the campus of the [US] National Institutes of Health, will be empowered by FEI's Titan Krios transmission electron microscope (TEM), the world's most powerful commercially-available electron microscope for structural biology.

The collaboration effort will focus on the development of methods and workflows, from sample preparation through data analysis, which combine information from cryo-EM, XRD, and NMR. More...
Researchers have historically relied on NMR and XRD techniques to determine the structures of molecular complexes and proteins that play a role in the causes of various disease states. Structural information about a variety of medically important proteins and drugs has been obtained by NMR and XRD methods. Cryo-EM is a complementary analytical technique that provides near-atomic resolution without requirements for crystallization or limits on molecular size and complexity imposed by the other techniques.

Dr. Don Kania, president and CEO of FEI, said, “This collaborative effort with NIH is a critical part of our strategy to provide complete microscopy solutions for life science research. Our life sciences business has been increasing rapidly and is a key part of our overall corporate growth plan. Helping our customers to obtain increased value from electron microscopy in conjunction with and complementary to XRD and NMR is a key element of that plan.”

Related Links:

FEI
National Institutes of Health



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.